TWI728994B - 血漿ｄｎａ之單分子定序 - Google Patents
血漿ｄｎａ之單分子定序 Download PDFInfo
- Publication number
- TWI728994B TWI728994B TW105125873A TW105125873A TWI728994B TW I728994 B TWI728994 B TW I728994B TW 105125873 A TW105125873 A TW 105125873A TW 105125873 A TW105125873 A TW 105125873A TW I728994 B TWI728994 B TW I728994B
- Authority
- TW
- Taiwan
- Prior art keywords
- dna fragments
- plasma
- sequence
- dna
- serum
- Prior art date
Links
- 238000012163 sequencing technique Methods 0.000 title claims abstract description 118
- 108020004414 DNA Proteins 0.000 claims abstract description 437
- 239000012634 fragment Substances 0.000 claims abstract description 312
- 238000000034 method Methods 0.000 claims abstract description 151
- 108091028732 Concatemer Proteins 0.000 claims abstract description 71
- 210000002966 serum Anatomy 0.000 claims description 49
- 210000000349 chromosome Anatomy 0.000 claims description 38
- 125000003729 nucleotide group Chemical group 0.000 claims description 33
- 239000002773 nucleotide Substances 0.000 claims description 32
- 230000002759 chromosomal effect Effects 0.000 claims description 10
- 239000000758 substrate Substances 0.000 claims description 6
- 150000007523 nucleic acids Chemical group 0.000 abstract description 14
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract description 4
- 210000002381 plasma Anatomy 0.000 description 142
- 210000003754 fetus Anatomy 0.000 description 36
- 238000007672 fourth generation sequencing Methods 0.000 description 35
- 125000006850 spacer group Chemical group 0.000 description 32
- 239000012472 biological sample Substances 0.000 description 31
- 238000009826 distribution Methods 0.000 description 31
- 239000000523 sample Substances 0.000 description 28
- 206010028980 Neoplasm Diseases 0.000 description 20
- 210000004027 cell Anatomy 0.000 description 20
- 230000008774 maternal effect Effects 0.000 description 19
- 102000053602 DNA Human genes 0.000 description 18
- 238000005516 engineering process Methods 0.000 description 18
- 210000001766 X chromosome Anatomy 0.000 description 17
- 239000000306 component Substances 0.000 description 16
- 238000002360 preparation method Methods 0.000 description 15
- 238000004458 analytical method Methods 0.000 description 14
- 238000010586 diagram Methods 0.000 description 14
- 239000012530 fluid Substances 0.000 description 14
- 201000011510 cancer Diseases 0.000 description 12
- 230000011987 methylation Effects 0.000 description 12
- 238000007069 methylation reaction Methods 0.000 description 12
- 238000001712 DNA sequencing Methods 0.000 description 11
- 102000039446 nucleic acids Human genes 0.000 description 11
- 108020004707 nucleic acids Proteins 0.000 description 11
- 210000002593 Y chromosome Anatomy 0.000 description 10
- 230000008569 process Effects 0.000 description 10
- 230000002159 abnormal effect Effects 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- 230000001605 fetal effect Effects 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 238000005119 centrifugation Methods 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 230000003287 optical effect Effects 0.000 description 7
- 230000008439 repair process Effects 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 102000003960 Ligases Human genes 0.000 description 6
- 108090000364 Ligases Proteins 0.000 description 6
- 230000004075 alteration Effects 0.000 description 6
- 208000036878 aneuploidy Diseases 0.000 description 6
- 231100001075 aneuploidy Toxicity 0.000 description 6
- 230000000295 complement effect Effects 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 238000003860 storage Methods 0.000 description 6
- 108700028369 Alleles Proteins 0.000 description 5
- 238000000605 extraction Methods 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 230000035935 pregnancy Effects 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 230000008859 change Effects 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 239000007850 fluorescent dye Substances 0.000 description 4
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 4
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 4
- 230000035772 mutation Effects 0.000 description 4
- 238000005325 percolation Methods 0.000 description 4
- 239000011148 porous material Substances 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 108020004705 Codon Proteins 0.000 description 3
- 108091034117 Oligonucleotide Proteins 0.000 description 3
- 108091028664 Ribonucleotide Proteins 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 210000003917 human chromosome Anatomy 0.000 description 3
- 230000006607 hypermethylation Effects 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 239000002336 ribonucleotide Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 108020005031 Concatenated DNA Proteins 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 2
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 108091005764 adaptor proteins Proteins 0.000 description 2
- 102000035181 adaptor proteins Human genes 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 210000000601 blood cell Anatomy 0.000 description 2
- 239000012503 blood component Substances 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical class NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 238000013480 data collection Methods 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 239000005547 deoxyribonucleotide Substances 0.000 description 2
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 238000005304 joining Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000011528 liquid biopsy Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000013507 mapping Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- YACKEPLHDIMKIO-UHFFFAOYSA-L methylphosphonate(2-) Chemical compound CP([O-])([O-])=O YACKEPLHDIMKIO-UHFFFAOYSA-L 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 238000003793 prenatal diagnosis Methods 0.000 description 2
- 238000009598 prenatal testing Methods 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 125000002652 ribonucleotide group Chemical group 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 238000002864 sequence alignment Methods 0.000 description 2
- 230000000392 somatic effect Effects 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- VGONTNSXDCQUGY-RRKCRQDMSA-N 2'-deoxyinosine Chemical group C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC2=O)=C2N=C1 VGONTNSXDCQUGY-RRKCRQDMSA-N 0.000 description 1
- 206010000234 Abortion spontaneous Diseases 0.000 description 1
- 101710092462 Alpha-hemolysin Proteins 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 206010006223 Breast discharge Diseases 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 208000031404 Chromosome Aberrations Diseases 0.000 description 1
- 108091029523 CpG island Proteins 0.000 description 1
- 108091029430 CpG site Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- JZTPOMIFAFKKSK-UHFFFAOYSA-N O-phosphonohydroxylamine Chemical compound NOP(O)(O)=O JZTPOMIFAFKKSK-UHFFFAOYSA-N 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 108091093037 Peptide nucleic acid Proteins 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 229910052581 Si3N4 Inorganic materials 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 208000026928 Turner syndrome Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000002669 amniocentesis Methods 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000003822 cell turnover Effects 0.000 description 1
- 230000006800 cellular catabolic process Effects 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 231100000005 chromosome aberration Toxicity 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 239000012468 concentrated sample Substances 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 238000011038 discontinuous diafiltration by volume reduction Methods 0.000 description 1
- 229940059082 douche Drugs 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 102000054766 genetic haplotypes Human genes 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229910021389 graphene Inorganic materials 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 208000015994 miscarriage Diseases 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 230000003169 placental effect Effects 0.000 description 1
- 210000004910 pleural fluid Anatomy 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000004065 semiconductor Substances 0.000 description 1
- 210000003765 sex chromosome Anatomy 0.000 description 1
- 150000003377 silicon compounds Chemical class 0.000 description 1
- HQVNEWCFYHHQES-UHFFFAOYSA-N silicon nitride Chemical compound N12[Si]34N5[Si]62N3[Si]51N64 HQVNEWCFYHHQES-UHFFFAOYSA-N 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 208000000995 spontaneous abortion Diseases 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 210000001138 tear Anatomy 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6869—Methods for sequencing
- C12Q1/6874—Methods for sequencing involving nucleic acid arrays, e.g. sequencing by hybridisation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6869—Methods for sequencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/483—Physical analysis of biological material
- G01N33/487—Physical analysis of biological material of liquid biological material
- G01N33/48707—Physical analysis of biological material of liquid biological material by electrical means
- G01N33/48721—Investigating individual macromolecules, e.g. by translocation through nanopores
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
- G16B30/10—Sequence alignment; Homology search
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2521/00—Reaction characterised by the enzymatic activity
- C12Q2521/50—Other enzymatic activities
- C12Q2521/501—Ligase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2525/00—Reactions involving modified oligonucleotides, nucleic acids, or nucleotides
- C12Q2525/10—Modifications characterised by
- C12Q2525/151—Modifications characterised by repeat or repeated sequences, e.g. VNTR, microsatellite, concatemer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2525/00—Reactions involving modified oligonucleotides, nucleic acids, or nucleotides
- C12Q2525/10—Modifications characterised by
- C12Q2525/191—Modifications characterised by incorporating an adaptor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2525/00—Reactions involving modified oligonucleotides, nucleic acids, or nucleotides
- C12Q2525/10—Modifications characterised by
- C12Q2525/197—Modifications characterised by incorporating a spacer/coupling moiety
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2527/00—Reactions demanding special reaction conditions
- C12Q2527/146—Concentration of target or template
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2565/00—Nucleic acid analysis characterised by mode or means of detection
- C12Q2565/60—Detection means characterised by use of a special device
- C12Q2565/631—Detection means characterised by use of a special device being a biochannel or pore
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Bioinformatics & Computational Biology (AREA)
- Medical Informatics (AREA)
- Evolutionary Biology (AREA)
- Theoretical Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Nanotechnology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Investigating Or Analyzing Materials By The Use Of Electric Means (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562204396P | 2015-08-12 | 2015-08-12 | |
| US62/204,396 | 2015-08-12 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TW201718874A TW201718874A (zh) | 2017-06-01 |
| TWI728994B true TWI728994B (zh) | 2021-06-01 |
Family
ID=57983895
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW110115619A TWI793586B (zh) | 2015-08-12 | 2016-08-12 | 血漿dna之單分子定序 |
| TW105125873A TWI728994B (zh) | 2015-08-12 | 2016-08-12 | 血漿ｄｎａ之單分子定序 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW110115619A TWI793586B (zh) | 2015-08-12 | 2016-08-12 | 血漿dna之單分子定序 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11319586B2 (enExample) |
| EP (1) | EP3334843A4 (enExample) |
| JP (3) | JP6867045B2 (enExample) |
| CN (2) | CN115433769A (enExample) |
| AU (3) | AU2016305103C1 (enExample) |
| CA (1) | CA2995422A1 (enExample) |
| HK (1) | HK1248286A1 (enExample) |
| IL (3) | IL285795B (enExample) |
| MY (1) | MY188348A (enExample) |
| SA (1) | SA518390907B1 (enExample) |
| TW (2) | TWI793586B (enExample) |
| WO (1) | WO2017025059A1 (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7084470B2 (ja) | 2017-08-23 | 2022-06-14 | エフ．ホフマン－ラ ロシュ アーゲー | 酵素のスクリーニング法 |
| AU2018327337A1 (en) * | 2017-09-07 | 2020-04-30 | Coopersurgical, Inc. | Systems and methods for non-invasive preimplantation genetic diagnosis |
| EP3700856A4 (en) | 2017-10-26 | 2021-12-15 | Ultima Genomics, Inc. | METHODS AND SYSTEMS FOR SEQUENCE CALL |
| WO2019133756A1 (en) | 2017-12-29 | 2019-07-04 | Clear Labs, Inc. | Automated priming and library loading device |
| US12378603B2 (en) | 2018-04-20 | 2025-08-05 | The Regents Of The University Of California | Nucleic acid sequencing methods and computer-readable media for practicing same |
| WO2020185790A1 (en) | 2019-03-10 | 2020-09-17 | Ultima Genomics, Inc. | Methods and systems for sequence calling |
| AU2020296108B2 (en) | 2019-06-21 | 2023-08-03 | Coopersurgical, Inc. | Systems and methods for determining pattern of inheritance in embryos |
| CN115315513A (zh) * | 2019-11-25 | 2022-11-08 | 威廉马歇莱思大学 | 用于纳米孔测序的线性dna组装 |
| US20230249178A1 (en) | 2020-07-08 | 2023-08-10 | Roche Sequencing Solutions, Inc. | Split-pool synthesis apparatus and methods of performing split-pool synthesis |
| JP2023545478A (ja) | 2020-10-15 | 2023-10-30 | カパ バイオシステムズ，インコーポレイティド | 次世代配列決定ライブラリ調製のための電気泳動デバイスおよび方法 |
| CN114507708A (zh) * | 2020-11-16 | 2022-05-17 | 唐纳德·李 | 一种制备长分子测序dna的方法 |
| EP4308723B1 (en) | 2021-03-15 | 2025-04-23 | F. Hoffmann-La Roche AG | Targeted next-generation sequencing via anchored primer extension |
| JP7657961B2 (ja) | 2021-03-26 | 2025-04-07 | エフ． ホフマン－ラ ロシュ アーゲー | ハイブリダイゼーション緩衝調合物 |
| WO2022207682A1 (en) | 2021-04-01 | 2022-10-06 | F. Hoffmann-La Roche Ag | Immune cell counting of sars-cov-2 patients based on immune repertoire sequencing |
| EP4323539A4 (en) * | 2021-04-12 | 2025-02-05 | The Chinese University of Hong Kong | ANALYSIS OF BASE MODIFICATION USING ELECTRICAL SIGNALS |
| WO2023023561A1 (en) * | 2021-08-17 | 2023-02-23 | Quantapore, Inc. | Multiplex binding assays with optical nanopore readout |
| WO2023067597A1 (en) * | 2021-10-18 | 2023-04-27 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Use of nanopore sequencing for determining the origin of circulating dna |
| US20250368983A1 (en) | 2022-06-30 | 2025-12-04 | Kapa Biosystems, Inc. | Controlling for tagmentation sequencing library insert size using archaeal histone-like proteins |
| CN114898802B (zh) * | 2022-07-14 | 2022-09-30 | 臻和(北京)生物科技有限公司 | 基于血浆游离dna甲基化测序数据的末端序列频率分布特征确定方法、评价方法及装置 |
| JP2025528488A (ja) | 2022-09-02 | 2025-08-28 | エフ． ホフマン－ラ ロシュ アーゲー | 次世代標的濃縮性能の改善 |
| WO2024215528A1 (en) | 2023-04-13 | 2024-10-17 | Ventana Medical Systems, Inc. | Proliferation assay for fixed solid tumors |
| WO2024256358A2 (en) | 2023-06-14 | 2024-12-19 | F. Hoffmann-La Roche Ag | Accelerated marking of 5-formyl cytosine and use in nucleic acid methylation sequencing |
| WO2025193604A1 (en) | 2024-03-11 | 2025-09-18 | Ventana Medical Systems, Inc. | Non-enzymatic dissociation of ffpe tissue and generation of single cells with intact cell surface markers |
| WO2025210056A1 (en) | 2024-04-03 | 2025-10-09 | Roche Sequencing Solutions, Inc. | In vitro amplification of dna methylation patterns |
| WO2025247632A1 (en) | 2024-05-27 | 2025-12-04 | European Molecular Biology Laboratory | Preparation of cell-free fragmented nucleic acids for genetic analysis sequencing |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006095169A1 (en) * | 2005-03-08 | 2006-09-14 | Lingvitae As | Method for preparing polynucleotides for analysis |
| US20120045771A1 (en) * | 2008-12-11 | 2012-02-23 | Febit Holding Gmbh | Method for analysis of nucleic acid populations |
| WO2012060595A2 (en) * | 2010-11-01 | 2012-05-10 | Lg Electronics Inc. | Structure with nanopore and apparatus for determining sequences of nucleic acids including the same |
| US20130040827A1 (en) * | 2011-08-14 | 2013-02-14 | Stephen C. Macevicz | Method and compositions for detecting and sequencing nucleic acids |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020197618A1 (en) * | 2001-01-20 | 2002-12-26 | Sampson Jeffrey R. | Synthesis and amplification of unstructured nucleic acids for rapid sequencing |
| JP2008161056A (ja) | 2005-04-08 | 2008-07-17 | Hiroaki Mita | Ｄｎａ配列解析装置、ｄｎａ配列解析方法およびプログラム |
| KR102222378B1 (ko) | 2007-07-23 | 2021-03-04 | 더 차이니즈 유니버시티 오브 홍콩 | 핵산 서열 불균형의 결정 |
| BRPI0922411A2 (pt) | 2008-12-11 | 2018-06-05 | Pacific Biosciences California Inc | classificação de templates de ácido nucléico |
| HUE061110T2 (hu) | 2009-11-05 | 2023-05-28 | Univ Hong Kong Chinese | Magzati genomelemzés anyai biológiai mintából |
| WO2011054936A1 (en) | 2009-11-06 | 2011-05-12 | The Chinese University Of Hong Kong | Size-based genomic analysis |
| US9121823B2 (en) * | 2010-02-19 | 2015-09-01 | The Trustees Of The University Of Pennsylvania | High-resolution analysis devices and related methods |
| KR101891847B1 (ko) | 2010-11-30 | 2018-08-24 | 더 차이니즈 유니버시티 오브 홍콩 | 암과 연관된 유전적 또는 분자적 이상들의 검출 |
| IN2014DN00221A (enExample) * | 2011-07-25 | 2015-06-05 | Oxford Nanopore Tech Ltd | |
| CA2840418C (en) * | 2011-07-26 | 2019-10-29 | Verinata Health, Inc. | Method for determining the presence or absence of different aneuploidies in a sample |
| WO2013109970A1 (en) | 2012-01-20 | 2013-07-25 | Genia Technologies, Inc. | Nanopore based molecular detection and sequencing |
| GB2559073A (en) * | 2012-06-08 | 2018-07-25 | Pacific Biosciences California Inc | Modified base detection with nanopore sequencing |
| WO2013188841A1 (en) * | 2012-06-15 | 2013-12-19 | Genia Technologies, Inc. | Chip set-up and high-accuracy nucleic acid sequencing |
| US11261494B2 (en) | 2012-06-21 | 2022-03-01 | The Chinese University Of Hong Kong | Method of measuring a fractional concentration of tumor DNA |
| GB201215449D0 (en) | 2012-08-30 | 2012-10-17 | Zoragen Biotechnologies Llp | Method of detecting chromosonal abnormalities |
| LT3354747T (lt) | 2012-09-20 | 2021-04-12 | The Chinese University Of Hong Kong | Neinvazinis naviko metilomos nustatymas iš plazmos |
| WO2015089333A1 (en) * | 2013-12-11 | 2015-06-18 | Accuragen, Inc. | Compositions and methods for detecting rare sequence variants |
| CN107002130B (zh) | 2014-11-11 | 2022-02-01 | 深圳华大基因研究院 | 多程测序 |
| AU2016406443A1 (en) | 2016-05-10 | 2018-11-15 | Nec Corporation | Demand and supply adjustment system, control apparatus, control method, and program |
-
2016
- 2016-08-12 IL IL285795A patent/IL285795B/en unknown
- 2016-08-12 CA CA2995422A patent/CA2995422A1/en active Pending
- 2016-08-12 JP JP2018506601A patent/JP6867045B2/ja active Active
- 2016-08-12 WO PCT/CN2016/094802 patent/WO2017025059A1/en not_active Ceased
- 2016-08-12 CN CN202211147693.8A patent/CN115433769A/zh active Pending
- 2016-08-12 EP EP16834683.1A patent/EP3334843A4/en active Pending
- 2016-08-12 MY MYPI2018000139A patent/MY188348A/en unknown
- 2016-08-12 AU AU2016305103A patent/AU2016305103C1/en active Active
- 2016-08-12 TW TW110115619A patent/TWI793586B/zh active
- 2016-08-12 HK HK18108082.2A patent/HK1248286A1/zh unknown
- 2016-08-12 US US15/235,630 patent/US11319586B2/en active Active
- 2016-08-12 TW TW105125873A patent/TWI728994B/zh active
- 2016-08-12 CN CN201680046621.0A patent/CN107849607B/zh active Active
-
2018
- 2018-01-22 IL IL257074A patent/IL257074B/en unknown
- 2018-02-12 SA SA518390907A patent/SA518390907B1/ar unknown
-
2020
- 2020-03-26 AU AU2020202153A patent/AU2020202153B2/en active Active
-
2021
- 2021-03-31 JP JP2021060027A patent/JP7506408B2/ja active Active
-
2022
- 2022-03-18 US US17/698,574 patent/US20220205038A1/en active Pending
- 2022-06-22 IL IL294192A patent/IL294192B2/en unknown
-
2023
- 2023-04-27 AU AU2023202572A patent/AU2023202572B2/en active Active
-
2024
- 2024-06-07 JP JP2024092950A patent/JP2024113130A/ja active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006095169A1 (en) * | 2005-03-08 | 2006-09-14 | Lingvitae As | Method for preparing polynucleotides for analysis |
| US20120045771A1 (en) * | 2008-12-11 | 2012-02-23 | Febit Holding Gmbh | Method for analysis of nucleic acid populations |
| WO2012060595A2 (en) * | 2010-11-01 | 2012-05-10 | Lg Electronics Inc. | Structure with nanopore and apparatus for determining sequences of nucleic acids including the same |
| US20130040827A1 (en) * | 2011-08-14 | 2013-02-14 | Stephen C. Macevicz | Method and compositions for detecting and sequencing nucleic acids |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7506408B2 (ja) | 血漿ｄｎａの単分子配列決定 | |
| TWI867325B (zh) | 利用血漿中dna的尺寸及數量畸變以偵測癌症 | |
| JP6161607B2 (ja) | サンプルにおける異なる異数性の有無を決定する方法 | |
| TWI727938B (zh) | 血漿粒線體ｄｎａ分析之應用 | |
| CN108026572A (zh) | 游离dna的片段化模式的分析 | |
| CN104254618A (zh) | 母体血浆中胎儿dna分数的基于大小的分析 | |
| CN110023509A (zh) | 基因型分型测定中的非独特条形码 | |
| HK40083172A (en) | Single-molecule sequencing of plasma dna | |
| HK1245850B (en) | Single-molecule sequencing of plasma dna | |
| HK1246361B (zh) | 母体血浆中胎儿dna分数的基於大小的分析 | |
| HK1245842B (zh) | 母体血浆中胎儿dna分数的基於大小的分析 | |
| HK1237825A1 (en) | Applications of plasma mitochondrial dna analysis | |
| HK1240279B (zh) | 使用血浆dna的尺寸和数目畸变检测癌症 |